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The BRCA1 tumor suppressor exists as a heterodimeric com-
plex with BARD1, and this complex is thought to mediate many
of the functions ascribed to BRCA1, including its role in tumor
suppression. The two proteins share a common structural orga-
nization that features an N-terminal RING domain and two
C-terminal BRCT motifs, whereas BARD1 alone also contains
three tandem ankyrin repeats. In normal cells, the BRCA1/
BARD1 heterodimer is believed to enhance chromosome stabil-
ity by promoting homology-directed repair (HDR) of double
strand DNA breaks. Here we have investigated the structural
requirements for BARD1 in this process by complementation of
Bard1-null mouse mammary carcinoma cells. Our results dem-
onstrate that the ankyrin and BRCT motifs of BARD1 are each
essential for both chromosome stability and HDR. Tandem
BRCT motifs, including those found at the C terminus of
BARD1, are known to form a phosphoprotein recognitionmod-
ule. Nonetheless, the HDR function of BARD1 was not per-
turbed by synthetic mutations predicted to ablate the phospho-
recognition activity of its BRCT sequences, suggesting that
some functions of the BRCT domains are not dependent on
their ability to bind phosphorylated ligands. Also, cancer-
associated missense mutations in the BRCT domains of
BARD1 (e.g. C557S, Q564H, V695L, and S761N) have been
observed in patients with breast, ovarian, and endometrial
tumors. However, none of these was found to affect the HDR
activity of BARD1, suggesting that any increased cancer risk
conferred by these mutations is not because of defects in this
repair mechanism.
Inactivatingmutations in the BRCA1 tumor suppressor gene
are found in a large proportion of hereditary breast and ovarian
cancers, underscoring the importance of the BRCA1 pathway
in modulating tumor susceptibility (1, 2). BRCA1 promotes
genomic stability through a number of cellular processes,
includingDNAdouble strand break (DSB)2 repair and cell cycle
checkpoint control (reviewed in Refs. 3–5). As such, cells defi-
cient in BRCA1 accumulate chromosome abnormalities and
display hypersensitivity to a variety of genotoxic agents.
Although the genome maintenance functions of BRCA1 are
believed to be a major determinant of its tumor suppression
activity, the specific molecular mechanisms by which BRCA1
affects genome stability remain elusive.
The BRCA1 gene encodes a 1863-amino acid protein with an
N-terminal RING domain and two tandem C-terminal BRCT
repeats (1, 6). In vivo, BRCA1 forms a stable heterodimer with
BARD1, a structurally related 777-amino acid protein that also
contains an N-terminal RING domain and two C-terminal
BRCT repeats (7). In addition, the central region of BARD1
harbors three tandem ankyrin repeats of unknown function.
The interaction between BRCA1 and BARD1 is mediated pri-
marily by N-terminal sequences encompassing their respective
RING domains (7, 8), and the resulting heterodimer functions
as a potent E3 ubiquitin ligase (9). As the enzymatic activity of
the BRCA1/BARD1 heterodimer is substantially higher than
that of the isolated polypeptides, the heterodimer is likely to
represent the physiologic mediator of BRCA1 and BARD1
functions. In support of this notion, Brca1- and Bard1-null
mice suffer embryonic lethality with phenotypes that are essen-
tially indistinguishable (10). Because embryonic cells from
these mice exhibit aneuploidy and accumulate chromosome
abnormalities, BARD1, like BRCA1, is likely to function in the
maintenance of genomic stability.
Given the intimate relationship between BRCA1 and
BARD1, lesions of the BARD1 gene might also be expected to
promote oncogenesis, and indeed, tumor-specific missense
mutations of BARD1 have been found in patients with breast,
ovarian, and endometrial carcinomas (11–13).Moreover, these
mutations are often accompanied by tumor-specific loss of the
normal BARD1 allele (11). Thus, although cancer-associated
BARD1 mutations are uncommon, their existence implies that
BARD1 can serve as a target for genetic lesions that disrupt
BRCA1-mediated tumor suppression. Experimental support
for this possibility has recently emerged from studies of mice
that undergo cre-mediated inactivation of the Bard1 gene in
their mammary epithelial cells. Remarkably, these animals
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develop breast tumors with an incidence, latency, and pheno-
type similar to those of mice undergoing mammary-specific
inactivation of Brca1.3 Thus, BARD1 appears to function in
vivo as a tumor suppressor in a manner reminiscent of BRCA1.
Recent studies have shown that two tandem BRCT motifs,
such as those arrayed at the C termini of BRCA1 and BARD1,
can form a structural domain that specifically binds phospho-
rylated peptide sequences (14, 15). In this manner, the BRCT
motifs of BRCA1 can control distinct cell cycle checkpoints
through phospho-dependent interactions with different cellu-
lar proteins. For example, the transient G2/M checkpoint
induced by ionizing radiation (IR) is dependent on recognition
of Ser-327-phosphorylated isoforms of the CtIP protein by the
BRCT motifs of BRCA1 (16). Conversely, an interaction
between these same motifs and the Ser-990-phosphorylated
BACH1/BRIP1/FancJ protein is required for activation of the
G2 accumulation checkpoint (15). Although cellular proteins
that associate with the BRCT motifs of BARD1 have not yet
beenidentified, thesemotifscanalsobindpeptides inaphospho-
dependent manner (17).
BRCA1 is required for homology-directed repair (HDR) of
DSBs (18, 19). In a previous study we showed that overexpres-
sion of a truncated BARD1 polypeptide interferes with HDR in
mouse embryonic stem cells, presumably through dominant-
negative inhibition of the endogenous Brca1/Bard1 het-
erodimer (20).More recently, the plant ortholog of BARD1was
shown to participate in homology-driven DNA recombination
in somatic cells (21). Because HDR is a major pathway for DSB
repair in mammals (22), the HDR defects associated with
BARD1 dysfunction may contribute to genomic instability.
Therefore, in the current study, we have investigated the struc-
tural requirements for BARD1 function in this process by
complementation of Bard1-null mouse mammary carcinoma
cell lines. Our results demonstrate that the ankyrin and BRCT
motifs of BARD1 are both essential for chromosomal stability
and HDR-mediated repair of an induced chromosomal break.
However, the HDR function of BARD1 was not perturbed by
synthetic mutations of the BRCT sequences predicted to ablate
phosphoprotein recognition. Thus, although the BRCT motifs
of BARD1 are critical for HDR, their ability to bind phospho-
rylated ligands does not appear to be required for this process.
Interestingly, although several cancer-associated missense
mutations of BARD1 target the BRCT domains, none of these
was found to affectHDR function, suggesting that the increased
cancer risk conferred by these variants is not because of defects
in HDR.
EXPERIMENTAL PROCEDURES
Cell Lines—Bard-null mouse mammary carcinoma cell lines
10-05 and 18-09 were grown in Dulbecco’s modified Eagle’s
medium supplementedwith 10% fetal bovine serum, 100g/ml
penicillin/streptomycin, and 2 mM L-glutamine. To generate
stably transformed subclones of these lines, 10-05 and 18-09
cells were transfected using FuGENE 6 (Roche Applied Sci-
ence) with either the empty pIRESpuro vector (Clontech) or
with the corresponding vector encoding human BARD1 with
either a single (FLAG-BARD1/pIRESpuro) or three tandem
(3xFLAG-BARD1/pIRESpuro) N-terminal FLAG epitopes.
Following 3 weeks of selection with 5 g/ml puromycin, indi-
vidual clones were screened for BARD1 expression by immu-
noblotting with BARD1- or FLAG-specific antibodies. To gen-
erate HDR reporter lines, Bard1-null 18-09 cells were
transfectedwith theDR-GFPhygro reporter construct (23), and
transformants harboring randomly integrated copies of the
reporter were selectedwith 0.25mg/ml hygromycin B. To iden-
tify subclones bearing a single intact copy of the reporter, the
genomic DNAs of individual subclones were digested with
restriction endonucleases (BglII, HindIII, PstI, and XbaI) and
analyzed by Southern hybridization with the 800-bp HindIII
fragment of the DR-GFPhygro plasmid. Two independently
derived subclones with a single integrated copy of the DR-GFP
reporter (18-09/DR-GFP-2 and 18-09/DR-GFP-4) were used
for all HDR experiments.
Antibodies—The BARD1-specific polyclonal antiserum has
been described (7). A monoclonal antibody (GH118) specific
for mouse Brca1 was kindly provided by Shridar Ganesan and
David Livingston (24). Other antibodies used included anti-
FLAG (M2, Sigma), anti-NuMa (Ab-1, Calbiochem), and anti-
-tubulin (Ab-1, Oncogene Science Inc.).
Cytogenetic Analysis—Cells in log phase of growth were
treated with colcemid for 2 h, trypsinized, washed with PBS,
and subjected to hypotonic treatment with 0.38% KCl at 37 °C
for 20 min. After fixing in 3:1 methanol/glacial acetic acid, the
cells were placed on glass slides and stained with Giemsa
(Karyomax, Invitrogen). Metaphase spreads were examined for
the presence of chromatid-type aberrations, including breaks,
gaps, and exchanges. Statistical analysis was performed using
the Simple Interactive Statistical Analysis website. Fisher’s
exact test was used for analysis of cytogenetic data. Multicolor
spectral karyotype analysis was performed on metaphase prep-
arations from Bard1-null carcinoma cells grown in culture
using standard procedures as recommended by the manufac-
turer (Applied Spectral Imaging, Vista, CA).
HDRAssays—Tomeasure repair of an I-SceI-inducedDSB in
the stably reconstituted 18-09/DR-GFP-2 reporter subclones
(e.g. Fig. 3), 4  105 cells/well were seeded in 2 ml of nonse-
lective medium on 6-well plates. After 20–24 h (at70% con-
fluency), the cells were transfected with 0.5 g of an I-SceI
expression vector (pCBASce) (26) or the corresponding empty
vector (pCAGGS) using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. At 18 h after trans-
fection, the cells were washed and replated on 60-mm dishes in
nonselective medium. Flow cytometric analysis to quantify the
presence of GFP-positive cells was performed 2 days later on a
FACSCalibur using Cellquest software (BD Biosciences). For
each sample, 50,000–100,000 cells were assessed, and the per-
centage of GFP-positive cells was calculated and displayed in
Figs. 3–5. An independent transfection with a GFP-encoding
vector was performed concurrently to provide a control for
transfection efficiency. To measure HDR in transiently recon-
stituted 18-09/DR-GFP-2 and -4 subclones (e.g. Figs. 4 and 5), 5
105 reporter cells were seeded on 60-mmplates, allowed to attach
for 20–24 h, and co-transfected with 1 g of pCBASce or the
3 R. Shakya, M. Szabolcs, E. E. McCarthy, E. Ospina, K. Basso, S. V. Nandula, V. V.
Murty, R. Baer, and T. Ludwig, unpublished data.
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corresponding empty vector (pCAGGS) and 2 g of pIRESpuro
expression vector encoding 3xFLAG-BARD1 or the correspond-
ing empty vector.At 18h after transfection, the cellswere replated
on 100-mm dishes. All other steps were performed as above.
RESULTS
The Ongoing Chromosomal Instability of Bard1-null Tumor
Cells Is Ameliorated by Exogenous BARD1—To study the con-
tribution of BARD1 to genomic stability, we examined BARD1
function in mouse mammary tumor cell lines that lack endog-
enous Bard1 expression. These lines were derived from tumors
that developed inmice harboring a conditionalBard1 allele that
was specifically inactivated in mammary epithelial cells by cre-
mediated recombination.3 Cytogenetic analysis of these lines,
including the two used in this study (10-05 and 18-09), revealed
aneuploid karyotypes exhibiting highly complex chromosomal
rearrangements (see Fig. 1A for a spectral karyotype of the
10-05 tumor line). Giemsa-stained metaphase spreads of each
line also displayed a high frequency of chromatid-type aberra-
tions, indicative of ongoing chromosomal instability (data not
shown). To determine whether Bard1 inactivation was respon-
sible for the ongoing chromosomal
instability, we asked whether
complementation with exogenous
BARD1 would ameliorate this phe-
notype and correct the chromo-
somal instability phenotype. There-
fore, isogenic subclones of the 10-05
Bard1-null tumor line were gener-
ated by stable transfection with an
empty mammalian expression vec-
tor or a vector that encodes the
human BARD1 polypeptide with an
N-terminal FLAG epitope (FLAG-
BARD1). As shown in Fig. 1B,
expression of exogenous BARD1
resulted in a proportional increase in endogenous Brca1 levels,
indicating that human BARD1 can interact with and stabilize
the mouse Brca1 polypeptide. Karyotype analysis of two inde-
pendently derived BARD1-complemented subclones and two
empty vector control subclones revealed amarked reduction in
the frequency of chromatid-type aberrations in cells reconsti-
tuted with BARD1. Thus, the percentage of metaphases with
one or more of these abnormalities was much lower in the
BARD1-complemented subclones (11%) than in the empty vec-
tor controls (26%) (Table 1).
To assesswhether complementationwith BARD1would also
reduce chromosomal instability induced by genotoxic stress,
cells were exposed to the DNA cross-linking agent mitomycin
C (MMC).MMC treatment resulted in increased levels of chro-
matid-type aberrations in both the BARD1-complemented
subclones and the control subclones (Table 1). Significantly,
however, the percentage of MMC-treated cells displaying
abnormal metaphases was lower for the BARD1-comple-
mented subclones (53%) than for the control subclones (70%).
The difference was more pronounced when considering the
number of metaphases displaying multiple aberrations; for
example, although MMC-treated metaphases harboring three
or more chromatid-type aberrations were rarely found in
BARD1-reconstituted subclones (5%), these were clearly more
prevalent in the control subclones (25%). These results indicate
that the chromosomal instability phenotype of Bard1-null
tumor cells is caused, at least in part, by loss of Bard1.
The Ankyrin and BRCT Motifs of BARD1 Are Necessary for
Maintenance of Chromosomal Stability—We previously
showed that a truncated formof BARD1 lacking the C-terminal
575 amino acids, including the three ankyrin and the two BRCT
repeats, exerts a dominant-negative effect on HDR of DSBs
(20). This suggests that one or both of these functional domains
is important for maintenance of chromosomal stability. To
assess the structural requirements for BARD1 in this process,
isogenic subclones of 10-05 cells were generated by stable
transformation with vectors encoding FLAG-tagged human
BARD1 polypeptides that lack either the three ankyrin repeats
encoded by amino acids 426–521 (BARD1-Ank) or the two
BRCT repeats encoded by amino acids 602–777 (BARD1-
BRCT) (Fig. 2A). As shown in Fig. 2B, the range of BARD1
protein expression in these subcloneswas comparablewith that
observed for the subclones complemented with full-length
FIGURE 1. Reconstitution of Bard-null cells with human BARD1. A, representative spectral karyotype of a
Bard1-null carcinoma cell line (10-05) showing aneuploidy and structural chromosome aberrations. B, sub-
clones of Bard1-null 10-05 cells stably transformed with an expression vector encoding human BARD1 (lanes
1–4) or the empty vector (lane 5) were analyzed by immunoblotting with antibodies specific for mouse Brca1,
humanBARD1, or-tubulin. The endogenous levels ofmouse Brca1 (lane 5) are increasedupon stable comple-
mentation with human BARD1 (lanes 1–4).
TABLE 1
The chromosomal instability of Bard1-null mammary carcinoma cells











>1 >2 >3 >4
MMC Empty vectorb 100 26 6 1 0
BARD1 95 11 1 1 0
BARD1-Ankc 100 30 9 4 1
BARD1-BRCTd 100 33 9 1 1
MMC Empty vectore 100 70 44 25 10
BARD1 100 53 17 5 2
BARD1-Ankf 100 78 56 32 14
BARD1-BRCTg 106 71 39 23 16
a Thepercentage ofmetaphases containing one ormore chromatid-type aberrations
(breaks, gaps, and/or exchanges) are shown. The difference in the percentage of
abnormal metaphases between subclones reconstituted with full-length BARD1
and either empty vector, BARD1-Ank, or BARD1-BRCT is statistically signif-
icant. Pairwise comparison using the Fisher’s exact test (25) on number of met-
aphases with1 aberration(s) is shown below.
b Values are p 3.0 103.
c Values are p 4.5 104.
d Values are p 9.1 105.
e Values are p 5.5 103.
f Values are p 1.1 104.
g Values are p 3.7 103.
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BARD1. Also, expression of either BARD1-Ank or BARD1-
BRCT increased endogenous Brca1 levels to a similar extent
as full-length BARD1, indicating that the ankyrin and BRCT
deletions do not impair the ability of these polypeptides to het-
erodimerize with and stabilize mouse Brca1.
Two subclones expressing each of the BARD1 deletion
mutants, matched by expression level to the full-length
BARD1-complemented subclones, were then subjected to
cytogenetic analysis. In contrast to full-length BARD1, stable
expression of the mutant BARD1 polypeptides failed to restore
chromosomal stability (Fig. 2C and Table 1). Thus, the propor-
tion of metaphases bearing spontaneous de novo chromatid-
type aberrations in the BARD1-Ank (30%) and BARD1-
BRCT (33%) subclones was comparable with that of the
control subclones (26%) and sig-
nificantly higher than that of sub-
clones reconstituted with full-
length BARD1 (11%). Whereas
MMC exposure increased the levels
of chromatid-type aberrations in all
subclones, the proportion of abnor-
mal metaphases was greater in the
control (70%), BARD1-Ank (78%),
and BARD1-BRCT (71%) sub-
clones than in those reconstituted
with full-length BARD1 (53%).
Again, this effect was more pro-
nounced when considering met-
aphases that harbor multiple aber-
rations; thus, the number of
metaphase spreads displaying three
or more chromatid-type defects in
the BARD1-Ank (32%) and
BARD1-BRCT (23%) subclones
was similar to that in the control
subclones (25%) and significantly
greater than that in subclones
expressing full-length BARD1 (5%).
These data indicate that both the
ankyrin andBRCTmotifs of BARD1
are necessary for suppression of
both spontaneous and MMC-in-
duced chromosomal instability.
The RING, Ankyrin, and BRCT
Motifs of BARD1 Are Each Necessary
for Homology-directed Repair—To
gain insight into the mechanism of
BARD1-mediated chromosomal
stability, we examined the structural
requirements for BARD1 in the
HDR of DSBs. HDR function can be
examined in vivo using a DR-GFP
reporter system that measures
recombinational repair of an
induced chromosomal DSB (27).
Briefly, the reporter harbors two
distinct nonfunctional copies of the
GFP gene (Fig. 3A). The first copy
(SceGFP) is disrupted by an 18-bp insertion bearing the recog-
nition site for the rare-cutting endonuclease I-SceI, whereas the
second copy (iGFP) encodes only an internal region of the GFP
gene lacking the N- and C-terminal coding sequences. How-
ever, a functional GFP gene can be generated when a DNA
break triggered by I-SceI cleavage of SceGFP is repaired by
HDR using iGFP as the template, and such events can be accu-
rately quantified using flow cytometry (27).
To evaluate the effect of BARD1 on HDR, we generated
Bard1-null cells containing a chromosomal DR-GFP reporter
by transfecting the Bard1-null mammary carcinoma line 18-09
with the linearized DR-GFPhygro construct (23). Following
selection with hygromycin B, individual subclones were iso-
lated and screened by Southern analysis to identify those pos-
FIGURE2.TheankyrinandBRCTdomainsofBARD1arenecessary for chromosomal stability.A, schematic
representations of the full-length BARD1 polypeptide, the BARD1-Ank polypeptide lacking the three ankyrin
domains (amino acids 426–521), and the BARD1-BRCT polypeptide lacking the two BRCT repeats (amino
acids 602–777). B,Bard1-null 10-05 cells stably transformedwith full-length BARD1 (lanes 2, 3, 7, and 8), BARD1-
BRCT (lanes 9 and 10), BARD1-Ank (lanes 4 and 5), or the empty expression vector (lanes 1 and 6) were
analyzed by immunoblotting with antibodies specific for mouse Brca1, human BARD1, or -tubulin. The
endogenous levels of mouse Brca1 (lanes 1 and 6) are increased to a similar extent upon stable complementa-
tion with either full-length BARD1 (lanes 2, 3, 7, and 8), BARD1-BRCT (lanes 9 and 10), or BARD1-Ank (lanes 4
and 5). C andD, subclones complemented with full-length BARD1, BARD1-Ank, BARD1-BRCT, or the empty
expression vectorwere cultured in the presence or absence ofMMC. One hundredmetaphase spreads of each
type of complemented subclone (50 each from two independent subclones shown in B) were analyzed for the
presence of de novo chromatid breaks, gaps, and exchanges. C, the percentage of untreated cells displaying
these chromatid-type aberrations. D, the percentage of MMC-treated cells displaying these aberrations.
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sessing a single integrated copy of the intact reporter (supple-
mental Fig. 1). One of the DR-GFP subclones of 18-09 (18-09/
DR-GFP-2) was then transfected with an empty expression
vector or the same vector encoding a FLAG-tagged full-length
BARD1 polypeptide (3xFLAG-BARD1), and stably trans-
formed subclones were selected with puromycin. As expected,
BARD1 expression in the resultant subclones increased the
steady-state levels of endogenous Brca1 (Fig. 3B). To measure
HDR of an induced chromosomal DSB, the BARD1-comple-
mented and control subclones were evaluated for the appear-
ance of GFP-positive cells at 72 h after transient transfection
with an expression vector encoding the I-SceI endonuclease or
the empty control vector. To control for variability in transfec-
tion efficiency among the different subclones, independent
transfections with an expression vector encoding eGFP were
performed in parallel and used to normalize the results. In the
absence of I-SceI expression, very few GFP-positive cells were
generated in either the BARD1-complemented or control sub-
clones (0–0.01%) (Fig. 3C). These rare GFP-positive cells are
thought to result from spontaneous gene conversion events
(27). As expected, I-SceI expression increased the number of
GFP-positive cells in all samples, consistent with its ability to
induce HDR by producing chromosomal DSBs within the inte-
grated DR-GFP locus. Notably, the number of GFP-positive
cells generated was much greater for the BARD1-expressing
subclones (0.96, 3.99, and 3.81% for subclones A, B, and C,
respectively) than for the control subclones (0.21 and 0.04% for
subclones A and B). This observation indicates that exogenous
BARD1 expression up-regulates HDR in Bard1-null mammary
carcinoma cells, consistent with our previous observation that
Bard1 functions with Brca1 to promote HDR in mouse embry-
onic stem cells (20). Moreover, it indicates that reconstitution
of Bard-null DR-GFP reporter cells can serve as an assay to
investigate the structural requirements for BARD1 in HDR.
To determine whether the RING, ankyrin, or BRCT domains
of BARD1 are necessary for HDR, we evaluated the ability of
BARD1 polypeptides lacking these motifs to promote repair of
an induced chromosomal break. For these experiments,
BARD1 complementation of Bard1-null DR-GFP cells was
achieved by transient transfection with BARD1 expression vec-
tors (reporter cells of subclone 18-09/DR-GFP-4 were used in
Figs. 4 and 5, but the same results were also observedwith other
subclones). As shown in Fig. 4A, when a vector encoding wild-
type (i.e. full-length) BARD1 was transiently co-transfected
with I-SceI, the measured HDR efficiency of 18-09/DR-GFP-4
cells (1.08% GFP-positive cells) was much greater than the
base-line level observed when the corresponding empty vector
was introduced with I-SceI (0.19% GFP-positive cells). This
represents a 5.0-fold increase in HDR efficiency, which is com-
parable with, albeit in the lower range of the spectrum, that
observed in 18-09/DR-GFP-2 cells stably complemented with
wild-type BARD1 (Fig. 3C). In contrast, expression of BARD1-
Ank or BARD1-BRCT along with I-SceI increased HDR by
only 1.9- and 1.5-fold, respectively (0.36 and 0.30% GFP-posi-
tive cells), which is significantly lower than the increase pro-
duced by wild-type BARD1 (5.0-fold), despite the fact that the
expression levels of BARD1-Ank and BARD1-BRCT were
comparable with that of wild-type BARD1 (Fig. 4B). Thus, loss
of either structural motif greatly impairs the ability of BARD1
to promoteHDR. Likewise, a RING-onlymutant that lacks both
the ankyrin and BRCT sequences (B202; residues 1–202) also
induced HDR to levels (1.2-fold) significantly lower that wild-
typeBARD1 (5.0-fold). These data indicate that the ankyrin and
BRCTdomains are required for the full HDR activity of BARD1
(Fig. 4).
We also evaluated the HDR function of BARD1-RING, a














FIGURE 3. HDR defect of Bard1-null cells can be rescued by complemen-
tation with BARD1. A, schematic of the DR-GFP reporter construct used to
measure HDR. The reporter contains two nonfunctional copies of the GFP
gene: SceGFP and iGFP. A functional copy of the GFP gene can be generated
when an I-SceI-induced chromosomal break in SceGFP is repaired by homol-
ogy-directed repair using iGFP as the template, and the efficiency of HDR can
be estimated by the percentage of GFP-positive cells (as measured by flow
cytometry) (27). B, subclones of Bard-null DR-GFP reporter cells stably trans-
formed with an expression vector encoding human BARD1 (lanes 3–5) or the
empty vector (lanes 1 and 2) were analyzedby immunoblottingwith antibod-
ies specific for the FLAG epitope (to verify expression of the exogenous
3xFLAG-BARD1 polypeptide), mouse Brca1, and -tubulin. C, HDR efficiency
in clones stably complemented with exogenous BARD1. Three subclones
expressing 3xFLAG-BARD1 and two empty vector controls were transfected
with either I-SceI or the empty expression vector and assayed for the percent-
age of GFP positive cells. A representative experiment performed in triplicate
is shown. The values were normalized for transfection efficiency using inde-
pendent transfectionswith an enhancedGFP expression vector, and the error
bars indicate S.D.
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ankyrin and BRCTmotifs but lacks residues 34–126, including
the RING domain and the two flanking -helices that mediate
its interaction with BRCA1. When expressed in Bard1-null
18-09/DR-GFP-4 cells along with I-SceI, the BARD1-RING
polypeptide failed to increase HDR above the background level
observed with the empty expression vector (Fig. 4). Thus, the
RING domain and its flanking helices are absolutely required
for any level of BARD1-mediated HDR activity.
Cancer-associated Missense Mutations Do Not Affect the
HDR Function of BARD1—Missense mutations of BARD1
have been identified in sporadic cases of breast, ovarian, and
uterine carcinoma, as well as in patients with familial breast
or ovarian cancer (11–13). Intriguingly, all known cancer
variants of BARD1 are missense mutations, and most cluster
within or adjacent to the BRCT motifs. To evaluate the
impact of these lesions on BARD1-mediated HDR, we exam-
ined three BARD1 missense mutations (Q564H, V695L, and
S761N) that were identified in a screen of 150 sporadic
tumors (11). At least two of these mutations were accompa-
nied by tumor-specific loss of the other BARD1 allele
(Q564H and V695L) (11). The V695L and S761N mutations
were not present in normal cells of the patients, indicating
that they arose somatically during tumor development. The
other variant, Q564H, was a germ line alteration in a patient
who had developed primary carcinomas of the breast, ovary,
and endometrium. Because Q564H was not found in 300
normal individuals investigated in the original study (11) and
has not been reported in the cancer patients or correspond-
ing controls of subsequent BARD1 mutation studies, it may
represent a rare disease-causing germ line alteration. In
addition to these rare tumor mutations, we analyzed a com-
mon polymorphic variant of BARD1 (C557S) that also tar-
gets sequences adjacent to the BRCT motifs (11, 12, 28–31).
Because several studies have shown a higher frequency of the
C557S allele in patients with breast cancer than in control
populations, this variant of BARD1 may confer cancer sus-
ceptibility at a low penetrance (12, 28, 29, 31).
To investigate whether thesemutations affect theHDR func-
tion of BARD1,we tested the ability ofmutant BARD1polypep-
tides to promote repair at the DR-GFP locus of Bard-null
18-09/DR-GFP-4 cells (Fig. 5).
When co-expressed with I-SceI,
each of the FLAG-tagged mutant
BARD1 polypeptides significantly
increased the number of GFP-posi-
tive cells (C557S, 1.22%; Q564H,
1.42%; V695L, 1.22%; and S761N,
1.41%) over the base-line level
observed in the absence of BARD1
expression (0.19%). These increases
are statistically indistinguishable
from those obtained with wild-type
BARD1 (1.33%), and the expression
level of each mutant polypeptide
was nearly identical to that of wild-
type BARD1 (Fig. 5). These results
suggest that the heightened cancer
risk associated with the germ line
BARD1 variants (C557S and
Q564H) and the tumorigenicity of
FIGURE 4. Loss of the RING, ankyrin, or BRCT motifs decreases the efficiency of BARD1-mediated HDR.
A, Bard1-null DR-GFP reporter cells (subclone 18-09/DR-GFP-4) were co-transfected with I-SceI endonuclease
along with a vector encoding wild-type (i.e. full-length) BARD1, BARD1-Ank, BARD1-BRCT, BARD1-B202,
BARD1-RING, or the corresponding empty expression vector (pIRESpuro). Flow cytometry was performed
72 h post-transfection to quantify the number of GFP-positive cells. Average values from a representative
experiment performed in triplicate are shown, and the error bars indicate S.D. The efficiency of HDR relative to
thebackground level observed in the samples transfectedwith the empty expression vector is indicated above
each bar. B, verification of BARD1 protein expression in the transfected samples was performed by immuno-
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FIGURE 5. Cancer-associated missense mutations or phospho-binding pocket mutations do not decrease the efficiency of BARD1-dependent HDR.
A,Bard1-null DR-GFP reporter cells (subclone 18-09/DR-GFP-4)were co-transfectedwith I-SceI endonuclease alongwith a vector encodingwild-type BARD1or
the indicated BARD1 mutant or the corresponding expression vector (pIRESpuro). Flow cytometry was performed 72 h post-transfection to quantify the
number of GFP-positive cells. Average values from a representative experiment performed in triplicate are shown. The error bars indicate S.D. B, comparison of
BARD1 protein expression in transfected samples.
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the somatic BARD1mutations (V695L and S761N) are unlikely
to result from defects in HDR function.
The Phosphopeptide Binding Potential of the Tandem BRCT
Repeats of BARD1 Is Not Essential for HDR—The results in Fig.
4 indicate that the BRCT sequences of BARD1 are required for
full HDR activity. Because tandem BRCT repeats can form a
phosphopeptide-bindingmodule (14, 15, 17), we askedwhether
this property underlies the functional significance of this
domain for BARD1-mediated HDR. Structural analyses of tan-
dem BRCT repeats bound to their cognate phosphorylated
ligands have now been performed for two BRCT proteins as
follows: BRCA1 in complex with phosphopeptides derived
from either BACH1 or CtIP (32–35), and MDC1 in complex
with a phosphopeptide from H2AX (36). These studies iden-
tified the structural determinants underlying phosphopeptide
binding and showed that the amino acids responsible for phos-
phate recognition are also present in other BRCT proteins,
including BARD1. Indeed, the crystal structure of the BARD1
BRCT domains harbors a phosphoserine binding pocket that is
strikingly similar to those of BRCA1andMDC1 (37).Moreover,
the predicted phosphoserine contact residues in the BRCT
domains of human BARD1 (Ser-575 and Lys-619) are phyloge-
netically conserved in its rat, mouse, and frog orthologs. To
address whether the phosphopeptide binding activity of the
BRCT repeats of BARD1 is important for HDR, we asked
whethermutating these residues affects the ability of BARD1 to
promote this type of repair. To this end we generated BARD1
expression vectors bearing either an S575F or K619A missense
mutation. Mutation of the corresponding residues of BRCA1
(Ser-1655 and Lys-1702) has already been shown to disrupt
BRCT-mediated binding to Ser-990-phosphorylated BACH1
(32, 34). Therefore, Bard-null carcinoma cells with a single
chromosomally integrated DR-GFP reporter (18-09/DR-
GFP-4) were co-transfected with I-SceI endonuclease together
with an expression vector encoding either the wild-type or
mutant forms of BARD1. As shown in Fig. 5, the BARD1-S575F
andBARD1-K619Amutants inducedHDR repair at levels (1.16
and 1.37% GFP-positive cells, respectively) indistinguishable
from that obtained with wild-type BARD1 (1.33%). These
results suggest that phospho-specific binding of the BRCT
repeats of BARD1 to its ligands is not essential for HDR of an
induced chromosomal break.
DISCUSSION
The tumor suppressor activity of BRCA1 is thought to derive,
at least in part, from its ability to promote genome integrity
(3–5, 38). The data presented here establish that BARD1, the
heterodimeric partner of BRCA1, is required for maintenance
of chromosomal stability and HDR of DSBs. Specifically, we
show that complementation of Bard1-null mouse carcinoma
cells with exogenous BARD1 results in suppression of both
spontaneous andMMC-induced de novo chromatid-type aber-
rations. In contrast, BARD1 polypeptides lacking the three
ankyrin repeats or the two C-terminal BRCTmotifs fail to sup-
press formation of de novo chromatid-type abnormalities, indi-
cating that both domains are required formaintenance of chro-
mosomal stability by BARD1. Because chromatid-type
aberrations are likely to be initiated by DSBs, these results
imply a role for the ankyrin and BRCT sequences of BARD1
in the cellular response to DSBs. A C-terminal BARD1 seg-
ment encompassing these sequences was previously impli-
cated in homology-directed repair of DSBs, suggesting a
potential mechanism by which one or both of these domains
could contribute to chromosomal stability (20). Here we
exploited the availability of Bard1-null mousemammary car-
cinoma cell lines to develop a convenient assay to measure
the HDR function of BARD1, and we have used this system to
establish that the ankyrin and the BRCT motifs of BARD1
are both necessary for HDR.
At present, there a few clues as to the mechanisms by which
the ankyrin repeats of BARD1 contribute to HDR or chromo-
somal stability. However, it may be possible to draw insights
about the BRCT domains of BARD1 by considering the known
functions of the corresponding motifs in BRCA1. For example,
the BRCT sequences of BRCA1 are required for its recruitment
to IR-induced foci (41, 42), the presumptive sites of DNA dam-
age in cells exposed to ionizing radiation, and a similar role in
IR-induced foci recruitment has also been proposed for the
BRCT sequences of other repair proteins, including NBS1 and
MDC1 (43, 44). In addition, the G2/M checkpoint functions of
BRCA1 are effected through phosphorylation-dependent bind-
ing of its BRCT motifs to either the BACH1 or CtIP polypep-
tides (15, 16). Indeed, a recent study shows that the BRCA1/
BARD1 heterodimer forms at least two different protein
complexes with distinct cell cycle checkpoint functions, one
containing BACH1 and one containing CtIP (45).
Although BARD1 derivatives lacking either the ankyrin or
BRCT sequences were clearly defective in HDR function rela-
tive to full-length BARD1, each polypeptide does restore a
modest level of HDR activity to Bard1-null cells that is repro-
ducible and statistically significant (Fig. 4). In contrast, deletion
of the N-terminal RING domain completely abrogates the abil-
ity of BARD1 to rescue the repair defect of Bard-null cells. This
presumably reflects the fact that the deleted region encom-
passes sequences of BARD1 that mediate its interaction with
BRCA1 (7, 8). As such, the deletion is expected to profoundly
affect both the subcellular localization of BRCA1 (42, 46) and
the level of BRCA1/BARD1-associated E3 ubiquitin ligase
activity (9). The importance of this enzymatic activity for tumor
suppression is underscored by the fact that BRCA1 mutations
that inhibit ubiquitin transfer are among the most common
BRCA1missense mutations associated with familial breast and
ovarian cancer (9, 47, 48). Recently, the enzymatic activity of
BRCA1/BARD1was shown to regulate theG2/Mcheckpoint by
catalyzing damage-induced polyubiquitination of CtIP (49).
This finding illustrates the interplay between the E3 ubiquitin
ligase activity of theBRCA1/BARD1heterodimer and the phos-
pho-recognition function of its BRCT motifs. In light of our
data, it is also possible that BRCA1/BARD1 promotes HDR by
ubiquitinating other repair factors that interact with the
ankyrin or BRCT sequences of BARD1. The notion that
BRCA1/BARD1 coordinates the cellular response to genotoxic
stress by catalyzing the ubiquitination ofmultiple repair factors
is consistent with the observation that polyubiquitin chains
accumulate at DNA repair foci in a BRCA1/BARD1-dependent
manner (50, 51).
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Because the BRCT sequences of BARD1 exhibit phos-
phopeptide binding activity (17) and form a phosphoserine
binding pocket (37), we anticipate that some downstream func-
tions of BRCA1/BARD1may bemediated by phospho-depend-
ent interactions of BARD1 with other repair proteins. Struc-
tural studies have identified specific BRCT residues of BRCA1
and MDC1 that bind the phosphate group of their respective
phosphopeptide ligands (32–34, 44). These major contact res-
idues are also present in human BARD1 (Ser-575 and Lys-619)
and conserved phylogenetically in many BARD1 orthologs.
This evidence, together with its ability to bind model phos-
phopeptides in vitro (17), suggests that the BRCT domain of
BARD1 has the potential for phosphoprotein recognition.
Therefore, we asked whether the same property underlies the
functional requirement for the BRCT sequences of BARD1 in
HDR. To interfere with phospho-recognition by BARD1, we
substituted phospho-contact residue Ser-575 with a phenylala-
nine (S575F), thus mimicking a naturally occurring tumor-as-
sociated BRCA1 variant (S1655F), and we changed phospho-
contact residue Lys-619 to alanine (K619A). Corresponding
mutations in the BRCT repeats of BRCA1 not only abrogate
phosphopeptide binding in vitro (32, 34) but also disrupt for-
mation of IR-induced nuclear foci (32) and ablate G2/M check-
point activation by the BACH1 phospholigand (25). Neverthe-
less, neither mutation affected the ability of BARD1 to
participate in HDR, suggesting that the phosphopeptide binding
potential of its BRCTdomains is dispensable for BARD1-depend-
ent HDR (Fig. 5). This result is surprising in light of the fact that
BARD1polypeptideswithoutBRCTsequences (BARD1-BRCT)
are clearly defective in HDR activity (Fig. 4). Perhaps the BRCT
sequences of BARD1 can support distinct classes of protein-pro-
tein interactions that include not only “canonical” phospho-de-
pendent interactions comparable with thosemediated by the tan-
demBRCTmotifs of BRCA1 (15, 16) but alsononcanonical BRCT
interactions that may or may not require ligand phosphorylation.
Although the canonical phospho-dependent interactions of
BARD1 appear to be dispensable for HDR, they are probably
important for other BARD1-dependent functions, and perhaps it
is these functions that are targeted by some of the tumor-associ-
atedBARD1mutations studiedhere. Inanycase, the identification
of proteins that interact with the ankyrin and the BRCTmotifs of
BARD1 should provide important insights into themechanism of
BARD1-mediated HDR.
Because BARD1 appears to function as a tumor suppressor, it
is intriguing to considerwhether theHDR function of BARD1 is
responsible, at least in part, for its tumor suppression activity
and whether disease-associated lesions of BARD1 affect HDR
function. Surprisingly, however, none of the four tumor-asso-
ciated mutations tested here had an appreciable effect on the
HDR activity of BARD1 (Fig. 5). It is possible that some of the
BARD1 variants analyzed here do not represent true cancer-
causing alterations. In particular, there have been conflicting
reports as to whether the common germ line variant C557S
represents a benign polymorphism or a deleterious allele based
on epidemiological data collected from distinct, but ethnically
related, populations (28, 30). However, a large collaborative
analysis of 2906 breast and ovarian patients and 3591 controls
of Nordic ancestry revealed that the C557S variant is more fre-
quently observed in familial breast cancer patients with no
known mutations in the BRCA1/BRCA2 tumor suppressors
(6.8%) than in healthy controls (2.8%) or BRCA1/2 mutation-
positive families (2.2%), supporting the contention that this
mutation does confer increased cancer risk (31). In addition,
because the S761N alteration originally identified as a somatic
mutation accompanied by loss-of-heterozygosity in an endo-
metrial carcinosarcoma (11) was subsequently observed in a
breast tumor with no evidence of loss-of-heterozygosity (13),
we cannot rule out the possibility that S761N represents a non-
consequential genetic change. Nevertheless, whenBARD1mis-
sense alterations were evaluated using growth-suppressive and
apoptotic properties of ectopic BARD1 expression as a surro-
gate assay, all four of the mutations we examined (C557S,
Q564H, S761N, and V695L) exhibited altered activity and, as
such, were designated as deleterious BARD1 variants (13). In
any case, a possible interpretation of our data is that these
BARD1mutations represent separation-of-function alleles that
leave the HDR function of the BRCA1/BARD1 heterodimer
intact but disrupt a distinct aspect of its tumor suppression
activity. Indeed, at least one of these mutations (Q564H) is
known to disrupt the interaction of BRCA1/BARD1 with the
50-kDa subunit of the mRNA polyadenylation factor CstF,
leading to de-repression of mRNA processing following expo-
sure to genotoxic stress (39). Because BRCA1/BARD1 is also
thought to promote genome stability and tumor suppression
through its involvement in other cellular processes, such as
mitotic spindle assembly (40) and cell cycle checkpoint control
(3), further studies of the tumor-associated BARD1 mutations
should address their effect on these aspects of BRCA1/BARD1
function.
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